Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo

NCT ID: NCT01049360

Last Updated: 2017-02-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 128 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-12-31
• Study Completion Date: 2010-08-31

Brief Summary

The purpose of this study is to evaluate the efficacy of this multicenter, randomized, double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study comparing 2 fixed dose combinations (FDCs) of aclidinium bromide with formoterol fumarate or with placebo, aclidinium bromide and formoterol fumarate, all administered twice a day (BID) in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD) beginning with a 2-week run-in period and with a 7-10 day washout each between treatment period.

Conditions

Chronic Obstructive Pulmonary Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Aclidinium 400 μg / Formoterol 12 μg

Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)

Group Type: EXPERIMENTAL

Aclidinium 400 μg / Formoterol 12 μg

Intervention Type: DRUG

Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.

Aclidinium 400 μg / formoterol 6 μg

Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)

Group Type: EXPERIMENTAL

Aclidinium 400 μg / Formoterol 6 μg

Intervention Type: DRUG

Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.

Aclidinium 400 μg

Aclidinium bromide 400 μg administered twice-daily (BID)

Group Type: EXPERIMENTAL

Aclidinium 400 μg

Intervention Type: DRUG

Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.

Formoterol 12 μg

Formoterol fumarate 12 μg twice-daily

Group Type: ACTIVE_COMPARATOR

Formoterol 12 μg

Intervention Type: DRUG

Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.

Placebo

Placebo twice-daily

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.

Interventions

Aclidinium 400 μg / Formoterol 12 μg

Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.

Intervention Type: DRUG

Aclidinium 400 μg / Formoterol 6 μg

Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.

Intervention Type: DRUG

Aclidinium 400 μg

Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.

Intervention Type: DRUG

Formoterol 12 μg

Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.

Intervention Type: DRUG

Placebo

Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Understand the study procedures and be willing to participate in the study as indicated by signing the ICF and HIPAA form
• Be male or female aged 40 to 80 years, inclusive
• Have a diagnosis of stable, moderate to severe COPD (stages II and III) as defined by guidelines of the Global Initiative for Chronic Obstructive Lung Disease (2008)
• Be a current or former cigarette smoker with a smoking history of at least 10 pack-years
• Have post-albuterol/salbutamol FEV1 values ≥ 30% and < 80% of the predicted value. FEV1 will be measured at the Screening Visit (Visit 1) between 10 and 15 minutes after inhalation of albuterol/salbutamol.
• Have post-albuterol/salbutamol FEV1/FVC values < 70% (ie, 100 × post- albuterol/salbutamol FEV1/FVC < 70%).
• If female, be at least 1 year postmenopausal or surgically sterile (defined as having a hysterectomy or tubal ligation). Women of childbearing potential must have a negative serum β-human chorionic gonadotropin pregnancy test at screening
• Be in good stable health (as judged by the Investigator) other than the COPD, based on medical history, physical examination, ECG, spirometry, and clinical laboratory data evaluations
• Have COPD symptoms and FEV1 values at the time of randomization that are stable compared with those at Screening (Visit 1), according to the Investigator's medical judgment

Exclusion Criteria

• Have been hospitalized for an acute COPD exacerbation within 3 months before screening
• Have any respiratory tract infection (including the upper respiratory tract) or signs of a COPD exacerbation or respiratory infection in the 6 weeks before Screening (Visit 1).
• Have any clinically significant respiratory conditions other than COPD
• Have a history or presence of asthma verified from medical records
• Have used theophylline (including long-acting theophylline) within the previous 3 months before study entry
• Have Stage II hypertension, defined as systolic pressure of 160 and above, and diastolic pressure of 100 and above
• Chronic use of oxygen therapy ≥ 15 hours a day
• Have a history, current diagnosis, or presence of exercise-induced bronchospasm
• Have a body mass index ≥ 40 kg/m2
• Have participated in an pulmonary rehabilitation program within the previous 3 months
• Have clinically significant cardiovascular conditions
• Have uncontrolled infection resulting from human immunodeficiency virus and/or active hepatitis
• Have symptomatic prostatic hypertrophy and/or bladder neck obstruction.
• Have narrow-angle glaucoma
• Have a history of hypersensitivity reaction (including report of paradoxical bronchospasm) to inhaled anticholinergics (including aclidinium bromide), β2 adrenergic agonists, or any other inhaled medication or any component thereof
• Have a QTcB, as indicated in the centralized reading report, above 470 msec in the resting ECGs performed at Screening (Visit 1) and/or patients who are using medications that may prolong the QT interval
• Have clinically relevant abnormalities in the results of clinical laboratory tests, in ECG parameters other than QTc, in results of the physical examination,
• Have any concurrent medical condition that, in the judgment of the Investigator, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being
• Do not maintain regular day/night, waking/sleeping cycles (eg, patients with history of sleep apnea syndrome or any disease related with sleep disturbances such as restless legs syndrome or somnambulism)

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Esther Garcia, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Forest Investigative Site 0909

Glendale, Arizona, United States

Forest Investigative Site 2050

Pheonix, Arizona, United States

Forest Investigative Site 2029

Rancho Mirage, California, United States

Forest Investigative Site 1084

Stockton, California, United States

Forest Investigative Site 2045

Wheat Ridge, Colorado, United States

Forest Investigative Site 1152

Clearwater, Florida, United States

Forest Investigative Site 2053

Tampa, Florida, United States

Forest Investigative Site 2047

Tampa, Florida, United States

Forest Investigative Site 1431

North Dartmouth, Massachusetts, United States

Forest Investigative Site 2084

Summit, New Jersey, United States

Forest Investigative Site 1119

Elmira, New York, United States

Forest Investigative Site 2035

Elizabeth City, North Carolina, United States

Forest Investigative Site 1153

Raleigh, North Carolina, United States

Forest Investigative Site 2028

Cincinnati, Ohio, United States

Forest Investigative Site 2043

Medford, Oregon, United States

Forest Investigative Site 1106

Portland, Oregon, United States

Forest Investigative Site 1089

East Providence, Rhode Island, United States

Forest Investigative Site 1121

Spartanburg, South Carolina, United States

Forest Investigative Site 1498

San Antonio, Texas, United States

Forest Investigative Site 1129

Waco, Texas, United States

Countries

United States

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4066&filename=lac-md-27-synopsis.pdf

lac-md-27-synopsis

Other Identifiers

LAC-MD-27

Identifier Type: -

Identifier Source: org_study_id